ACQUISITION OF DOXAZOSIN GROUP MEDICINES

This tender, identified by process code SIE-CMFIEDM-2025-005-748941, concerns the procurement of medicines belonging to the Doxazosin group. The contracting entity is CENTRO MEDICO FAMILIAR INTEGRAL Y ESPECIALIDADES, DIALISIS LA MARISCAL. The procurement method specified is Electronic Reverse Auction.

The primary requirement detailed in this tender is for Doxazosin, specifically in an oral solid form, with a dosage of 2 mg. The medication is to be supplied in boxes containing blister packs or strips. The total quantity required is 120,000 units, with an estimated value of USD 96,300.00 for this item.

This procurement is crucial for ensuring the availability of essential medications for the patients served by the CENTRO MEDICO FAMILIAR INTEGRAL Y ESPECIALIDADES, DIALISIS LA MARISCAL. The use of an Electronic Reverse Auction modality suggests a competitive bidding process aimed at achieving the most favorable pricing for the specified pharmaceutical product. Interested suppliers are expected to meet the quality and quantity specifications outlined for Doxazosin 2 mg oral solid dosage forms. Further details regarding the tender process, submission deadlines, and specific technical requirements will be available through the electronic platform associated with the Electronic Reverse Auction.

This is a supplies contract in the governance and public administration sector. Located in Ecuador, Latin America, this opportunity is open to firms and consortiums, with an estimated budget of USD 96,300.

Published through SERCOP Ecuador, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the governance and public administration sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.